YD Bio (YDES) Interest Expenses (2024 - 2025)
YD Bio's (YDES) quarterly Interest Expenses came in at $552846.0 in Q4 2025, up 55686.68% year-on-year from N/an in Q4 2024, and up 55686.68% on a QoQ basis from $991.0 in Q4 2024.
YD Bio (YDES) Interest Expenses (2024 - 2025) Analysis & Trends
YD Bio (YDES) has 2 years of Interest Expenses data on file, last reported at $552846.0 in Q4 2025.
- On a quarterly basis, Interest Expenses rose 55686.68% year-over-year to $552846.0 in Q4 2025; TTM through Dec 2025 was $552846.0, a 55686.68% increase from a year earlier, with the FY2025 full-year figure at $552846.0, up 55686.68% from the prior year.
- Interest Expenses for Q4 2025 stood at $552846.0, up from $991.0 in the prior quarter.
- Over the last five years, Interest Expenses for YDES reached as high as $552846.0 in Q4 2025 and fell as low as $991.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -42,141.15 |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 100,000.00 |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 32.89 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 420.30 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 28.30 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 1.17 Bn |
| 10 | YD Bio | 157.46 Mn | 151.45 Mn | - | 552,846.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 552,846.00 |
| Dec 31, 2025 | 552,846.00 |
| Dec 31, 2024 | 991.00 |
| Dec 31, 2024 | 991.00 |